Assessing the side effects and resistance in H. pylori treatment: a discussion on minocycline versus tetracycline therapy
(Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 28, 2024 Category: Gastroenterology Source Type: research
Clinicopathological features and prognosis of primary small bowel adenocarcinoma: a large multicenter analysis of the JSCCR database in Japan
ConclusionsOf the patients with PSBA, 76.8% had symptoms at the initial diagnosis, which were often detected at an advanced stage. Detection during the early stages of PSBA is important to ensure a good prognosis. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 27, 2024 Category: Gastroenterology Source Type: research
Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis
ConclusionsOur results demonstrated that effective inhibition of IDO1 expression in macrophages in NASH alleviated hepatic parenchymal cell lipid accumulation and iron deposition, which provided new insights for the future treatment of NASH. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 24, 2024 Category: Gastroenterology Source Type: research
Acknowledgements
(Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 16, 2024 Category: Gastroenterology Source Type: research
Reply to: Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial
(Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 14, 2024 Category: Gastroenterology Source Type: research
Role of combined aerobic and resistance exercise in liver cirrhosis
(Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 8, 2024 Category: Gastroenterology Source Type: research
A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA
ConclusionsWe have identified SAG-524 as novel and orally bioavailable HBV-RNA destabilizers which can reduce HBsAg and HBV-DNA levels, and possibly contribute a functional cure.Graphical Abstract (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - February 5, 2024 Category: Gastroenterology Source Type: research
